Ampicillin and tetracycline, in doses of 2 g a day, were compared in the treatment of acute exacerbations of chronic bronchitis. Seventy-nine patients were followed for 3 to 29 months and were treated for 118 exacerbations. Clinical improvement occurred after 10 days of treatment with either drug in over 80% of the cases. Haemophilus influenzae and Diplococcus pneumoniae were eradicated from the sputum more than 60% of the time, but in general there was a poor correlation between bacteriological clearing and clinical response. The effect of chemoprophylaxis with ampicillin and tetracycline in doses of 1 g a day on the frequency of acute exacerbations of bronchitis was compared with that of a placebo. Seven hundred eighty prophylactic regimens, consisting of one capsule every 12 hr for 5 days beginning with the first sign of a cold, were prescribed for 76 patients. Irrespective of the regimen, an acute exacerbation of bronchitis was encountered at approximately 13% of the follow-up visits to the clinic.
Bacterial infection is probably not a primary etiologic factor in the development of simple chronic bronchitis in most patients. However, infection of the lower respiratory tract with a variety of bacteria including the potential pathogens Haemophilus influenzae and Diplococcus pneumoniae is almost universal in this disease (4, 8) , and it is generally recommended that patients with chronic airways obstruction receive antibiotics when they show signs of acute infection.
Although most studies have indicated that tetracycline and ampicillin in doses of 1 g daily are equally effective in the treatment of acute exacerbations of bronchitis (1, 3, 9) , May and Delves reported that ampicillin was slightly superior at these doses and at 4 g daily it clearly gave better results (10) . The current study was undertaken to evaluate the relative effectiveness of ampicillin and tetracycline in the treatment of acute exacerbations of chronic bronchitis at an intermediate dose of 2 g daily. The use of these drugs prophylactically at the first sign of a respiratory tract infection was also evaluated.
MATERIALS AND METHODS
Patients. One hundred fifty three patients with chronic bronchitis (according to the definition of the American Thoracic Society [2] , i.e., productive cough on most days three months out of the year for at least two successive years), were enrolled in the study during the 2.5 years it was in progress. The clinic records of 79 of these patients were sufficiently complete for analysis and form the basis of this study. These patients were followed for 3 to 29 months; there were 68 men and 11 women, with an average age of 60.5 years. Most of the patients had airways obstruction, and the mean forced expiratory volume in one second (FEVy) of the group on entrance to the study was 1.33 liters, with a range of 0.5 to 2.9 liters.
Protocol. Patients did not receive antibiotics during the first month in the study. In addition to history and physical examination, each patient had a chest X ray, hematocrit, leukocyte count, eosinophile count, urinalysis, routine blood chemistries, electrocardiogram, tuberculin and fungal skin tests, and screening pulmonary function tests as part of their initial evaluation. Patients were instructed to collect all the sputum they produced during the 24 hr prior to each clinic visit. The volume of these samples was measured, and the sputum was characterized arbitrarily as mucoid or purulent on the basis of visual assessment and the amount of foam produced in a standard test tube when 1 ml of hydrogen peroxide was mixed with 1 ml of sputum. At each visit, shortness of breath was graded according to an arbitrary scale, the FEVy was measured, and freshly expectorated sputum was collected for quantitative bacterial cultures.
Patients were assigned to one of four antibiotic regimens for treatment and prophylaxis in a random, double blind manner ( Effect of chemoprophylaxis. There were sufficient data on 76 patients to evaluate the effect of prophylaxis on the incidence of acute exacerbations of bronchitis. A prophylactic regimen was prescribed 780 times (one capsule every 12 hr for 5 days for 76 patients), and the patients were seen again within 4 to 8 weeks; a placebo was dispensed 354 times, and ampicillin or tetracycline were dispensed 213 times each ( Table 2) . Irrespective of the regimen prescribed, an acute exacerbation was encountered at approximately 13%C of the follow-up visits to the clinic. Although patients were instructed to take their drug only if they developed symptoms of a cold, most of them took the prescribed drug at some time between visits. When these results were analyzed only for those visits at which self administration of prophylaxis was carefully documented by history, the numbers were smaller, but the proportion of visits at which an acute exacerbation of bronchitis was encountered was still the same in all groups.
No effort was made to evaluate the effect of chemoprophylaxis on the severity of an acute attack of bronchitis.
DISCUSSION
The role of bacterial infection in the etiology of acute exacerbations of chronic bronchitis is not clear. Two separate lines of evidence suggest that most exacerbations are triggered by viral infection or by other factors such as atmospheric pollution rather than bacterial infection. Firstly, it was shown that rhinovirus infection in patients with chronic bronchitis usually causes a fullblown acute exacerbation, whereas in normal individuals it usually causes afebrile rhinorrhea (12). Secondly, studies have been reported in which chemoprophylaxis with a variety of antimicrobial agents failed to influence the frequency with which acute exacerbation of bronchitis occurred, suggesting that bacterial infections rarely initiated exacerbations (6, 11) . This is a controversial point, because others have reported a decrease in the number of exacerbations in patients receiving chemoprophylaxis during the winter (7). However, virtually all of these studies have demonstrated that administration of antibiotics significantly reduced the severity of exacerbations.
The results of the current study show that ampicillin and tetracycline are about equally effective in treating acute exacerbations of bronchitis. Sputum routinely converted from purulent to mucoid with therapy, and patients almost invariably were subjectively improved The only significant difference between tetracycline and ampicillin noted in this study was the higher frequency with which tetracycline eradicated Haemophilus species from the sputum. Ampicillin more consistently eradicated pneumococci, but the numbers were too small to substantiate this difference statistically. In view of the relatively poor correlation between clinical and bacteriological response to therapy, it is questionable whether either of these observations has practical meaning.
The failure of chemoprophylaxis initiated at the first sign of an upper respiratory tract infection to protect against development of acute exacerbations is not surprising. It was not possible in this study to assess the severity of exacerbations which developed in patients treated with placebo versus antibiotic, but others have shown that antibiotics administered early in the course of an exacerbation significantly modify its course. Therefore, if prophylaxis is recommended, it should be with this goal in mind, and intermittent administration of drugs should be as effective and less expensive than continuous prophylaxis.
All studies of this type suffer from the fact that too little is known about the role of bacterial infection in the etiology, pathogenesis, and natural history of chronic bronchitis. A study of patients with bronchitis in association with bronchiectasis indicated that those with frequent exacerbations had a higher mortality and more rapid deterioration of lung function over a period of years (5) . However, similar data are not available for patients with chronic bronchitis and obstructive pulmonary disease, and the use of antibiotics in this group is largely empiric. This and other studies indicate that ampicillin and VOL. 2, 1972 tetracycline are about equally effective in treating acute exacerbations of bronchitis, so the choice should depend on cost, history of allergy, and other factors.
